Crawford & Company (ESPR) Stock

Understand Crawford & Company: how it makes money

Esperion Therapeutics develops and commercializes medicines for elevated low density lipoprotein cholesterol, led by NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), and it also earns revenue through a licensing and collaboration arrangement with Daiichi Sankyo Europe and royalty economics connected to that partnership.

The profit model is tied to (1) commercializing its own lipid medicines in the U.S. and (2) converting partnership arrangements into collaboration revenue and partner royalty streams, so business execution depends on both internal product commercialization and external partner performance.

Business quality (Weak): The business mix includes U.S. product revenue plus collaboration and royalty components tied to partners, but the latest reported revenue appears to be influenced by a litigation-related settlement item, and the operating margin remains negative.

Bull case

• Commercial presence with two lead lipid-lowering medicines: Esperion’s lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) for patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
• Partner-supported revenue potential: Esperion has a license and collaboration agreement with Daiichi Sankyo Europe GmbH, creating collaboration revenue and royalty-related revenue categories.
• Go-to-market metrics track digital prescribing behavior: Operational KPIs include prescription activity by physicians using only digital touchpoints and new writer prescriptions driven by digital-only touchpoints.

Bear case

• Profitability is currently negative: The latest period shows an operating margin of -8.2%.
• Revenue may include non-recurring items: The revenue breakdown includes a category labeled, Litigation-Related Settlement Included in Revenue, with a candidate value of 0.1B.
• Partner dependence for part of the revenue stream: The business includes collaboration and royalty revenue categories tied to Daiichi Sankyo Europe, which can create exposure to partner-driven outcomes.

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Ardelyx, Inc. (ARDX)
• Innoviva, Inc. (INVA)
• Arcutis Biotherapeutics, Inc. (ARQT)
• Atea Pharmaceuticals, Inc. (AVIR)
• MannKind Corporation (MNKD)
• Nature's Sunshine Products, Inc. (NATR)
• BridgeBio Pharma, Inc. (BBIO)
• Mirum Pharmaceuticals, Inc. (MIRM)